Literature DB >> 22042485

The association of serum chemerin level with risk of coronary artery disease in Chinese adults.

Qun Yan1, Yifei Zhang, Jie Hong, Weiqiong Gu, Meng Dai, Juan Shi, Ying Zhai, Weiqing Wang, Xiaoying Li, Guang Ning.   

Abstract

Chemerin is a newly discovered adipokine which has been found closely associated with obesity, metabolic syndrome (MetS), and inflammatory status. This study will investigate whether serum chemerin levels are associated with coronary artery disease (CAD) independently of other cardiovascular risk factors. This study included a total of 430 subjects (239 with CAD and 191 with non-CAD) who underwent coronary angiography. Anthropometric measurements were performed and chemerin, glucose, lipid profiles, and other biochemical characteristics were measured. The severity of coronary atherosclerosis was estimated by the total number of diseased vessels and Gensini score. Serum chemerin levels were significantly higher in the CAD group than in the non-CAD group (P = 0.011). The odds ratios (95% CI) of CAD across increasing quartiles of serum chemerin were 1.04 (0.61-1.78), 1.08 (0.63-1.83), and 1.87 (1.07-3.24), (P = 0.386, 0.508, and 0.012, respectively). Adjusting for age, sex, and other conventional risk factors for CAD did not appreciably alter the results. Serum chemerin levels were significantly increased with an increasing of number of diseased vessels (P = 0.024). In conditional linear regression models, chemerin levels were positively related to Gensini score even after established cardiovascular risk factors (β = 0.13, P = 0.019). Correlation analysis showed serum chemerin levels were significantly associated with TG levels, TC levels, fasting serum insulin, HOMA-IR and MetS (all P < 0.05). Higher serum chemerin levels were associated with increased risk of CAD and metabolic parameters in Chinese adults. Chemerin may represent a novel link between metabolic signals and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22042485     DOI: 10.1007/s12020-011-9550-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

1.  The endothelial dysfunction in patients with type 2 diabetes mellitus is associated with IL-6 gene promoter polymorphism in Chinese population.

Authors:  Xianfeng Zhang; Lizhen Ma; Fengying Peng; Yin Wu; Yu Chen; Linying Yu; Zhikai Lei; Chu Zhang
Journal:  Endocrine       Date:  2011-03-18       Impact factor: 3.633

2.  Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes.

Authors:  Carmine Gazzaruso; Adriana Coppola; Tiziana Montalcini; Cinzia Valenti; Adriana Garzaniti; Gabriele Pelissero; Fabrizio Salvucci; Pietro Gallotti; Arturo Pujia; Colomba Falcone; Sebastiano B Solerte; Andrea Giustina
Journal:  Endocrine       Date:  2011-08-23       Impact factor: 3.633

3.  Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis.

Authors:  Sofia G Spiroglou; Christos G Kostopoulos; John N Varakis; Helen H Papadaki
Journal:  J Atheroscler Thromb       Date:  2010-02-10       Impact factor: 4.928

4.  Chemerin, a novel adipokine in the regulation of angiogenesis.

Authors:  Kiymet Bozaoglu; Joanne E Curran; Claire J Stocker; Mohamed S Zaibi; David Segal; Nicky Konstantopoulos; Shona Morrison; Melanie Carless; Thomas D Dyer; Shelley A Cole; Harald H H Goring; Eric K Moses; Ken Walder; Michael A Cawthorne; John Blangero; Jeremy B M Jowett
Journal:  J Clin Endocrinol Metab       Date:  2010-03-17       Impact factor: 5.958

Review 5.  Adiponectin action from head to toe.

Authors:  Karine Brochu-Gaudreau; Charlotte Rehfeldt; Richard Blouin; V Bordignon; Bruce D Murphy; Marie-France Palin
Journal:  Endocrine       Date:  2009-12-01       Impact factor: 3.633

Review 6.  Endothelial inflammation in insulin resistance.

Authors:  Ake Sjöholm; Thomas Nyström
Journal:  Lancet       Date:  2005 Feb 12-18       Impact factor: 79.321

Review 7.  Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis.

Authors:  Michael W Rajala; Philipp E Scherer
Journal:  Endocrinology       Date:  2003-09       Impact factor: 4.736

8.  Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes.

Authors:  Michiko Takahashi; Yutaka Takahashi; Kenichi Takahashi; Fyodor N Zolotaryov; Kyoung Su Hong; Riko Kitazawa; Keiji Iida; Yasuhiko Okimura; Hidesuke Kaji; Sohei Kitazawa; Masato Kasuga; Kazuo Chihara
Journal:  FEBS Lett       Date:  2008-01-31       Impact factor: 4.124

9.  Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction.

Authors:  Cyrus V Desouza; Frederick G Hamel; Keshore Bidasee; Kelly O'Connell
Journal:  Diabetes       Date:  2011-02-23       Impact factor: 9.461

10.  Synthetic chemerin-derived peptides suppress inflammation through ChemR23.

Authors:  Jenna L Cash; Rosie Hart; Andreas Russ; John P C Dixon; William H Colledge; Joanne Doran; Alan G Hendrick; Mark B L Carlton; David R Greaves
Journal:  J Exp Med       Date:  2008-04-07       Impact factor: 14.307

View more
  30 in total

1.  Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.

Authors:  Mohamed I Saad; Taha M Abdelkhalek; Moustafa M Saleh; Maher A Kamel; Mina Youssef; Shady H Tawfik; Helena Dominguez
Journal:  Endocrine       Date:  2015-08-14       Impact factor: 3.633

2.  Exercise-induced lowering of chemerin is associated with reduced cardiometabolic risk and glucose-stimulated insulin secretion in older adults.

Authors:  S K Malin; S D Navaneethan; A Mulya; H Huang; J P Kirwan
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

3.  New Biomarkers as Prognostic Factors for Cardiovascular Complications in Type 2 Diabetic Patients.

Authors:  Hanaa H Ahmed; Wafaa Gh Shousha; Hatem A El-Mezayen; Ibrahim A Emara; Marwa E Hassan
Journal:  Indian J Clin Biochem       Date:  2018-07-17

4.  Association of serum chemerin levels with the severity of coronary artery disease in patients with metabolic syndrome.

Authors:  Gökhan Aksan; Sinan İnci; Gökay Nar; Korhan Soylu; Ömer Gedikli; Serkan Yüksel; Metin Özdemir; Rukiye Nar; Murat Meriç; Mahmut Şahin
Journal:  Int J Clin Exp Med       Date:  2014-12-08

Review 5.  The Role of Adipocytokines in Coronary Atherosclerosis.

Authors:  Luca Liberale; Aldo Bonaventura; Alessandra Vecchiè; Matteo Casula; Franco Dallegri; Fabrizio Montecucco; Federico Carbone
Journal:  Curr Atheroscler Rep       Date:  2017-02       Impact factor: 5.113

6.  Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia.

Authors:  Liqiong Wang; Tianli Yang; Yiling Ding; Yan Zhong; Ling Yu; Mei Peng
Journal:  Endocrine       Date:  2014-05-20       Impact factor: 3.633

Review 7.  Chemerin: a potential endocrine link between obesity and type 2 diabetes.

Authors:  Alexandra A Roman; Sebastian D Parlee; Christopher J Sinal
Journal:  Endocrine       Date:  2012-05-19       Impact factor: 3.633

Review 8.  Chemerin as an independent predictor of cardiovascular event risk.

Authors:  Sinan İnci; Gökhan Aksan; Pınar Doğan
Journal:  Ther Adv Endocrinol Metab       Date:  2016-02-08       Impact factor: 3.565

9.  Serum chemerin and high-sensitivity C reactive protein as markers of subclinical atherosclerosis in Egyptian patients with type 2 diabetes.

Authors:  Nagwa A Lachine; Abdel Aziz Elnekiedy; Magdy Helmy Megallaa; Gihane I Khalil; Mohamed A Sadaka; Kamel H Rohoma; Heba S Kassab
Journal:  Ther Adv Endocrinol Metab       Date:  2016-03-10       Impact factor: 3.565

10.  Effects of chemerin/CMKLR1 in obesity-induced hypertension and potential mechanism.

Authors:  Chunyan Weng; Zhijie Shen; Xiaobo Li; Weihong Jiang; Liping Peng; Hong Yuan; Kan Yang; Jiangang Wang
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.